← Eichor
Study identifier: NCT05988814 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Condition: Metastatic Pancreatic Cancer  ·  Sponsor: Centre Georges Francois Leclerc

PhasePhase 2
Planned participants90
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Jean-David FUMET, Dr  ·  380737538  ·  jdfumet@cgfl.fr

Sophie PARNALLAND, Project manager  ·  345348077  ·  sparnalland@cgfl.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Centre Georges-François LeclercDijon, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05988814